BioStem Technologies Profit Margin

BioStem Technologies (BSEM) currently reports a profit margin of 64.03% as of September 2026. That compares with 8.59% in the prior-year period — up 645.4% year over year. That is above the Healthcare sector average of 19.13%. Use the charts on this page to explore BioStem Technologies's profit margin history and peer comparisons.

BioStem Technologies's profit margin increased from 8.59% to 64.03% — a 645.4% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioStem Technologies's profit margin of 64.03% is higher than the Healthcare sector average of 19.13%. That is roughly 234.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BioStem Technologies's current 64.03% should be judged against Healthcare norms (sector average: 19.13%) and against BSEM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 64.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for BioStem Technologies, and consider following BSEM for alerts when major investors trade the stock.